Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RelA life and death decisions.

Shigeki Miyamoto1

  • 1Department of Pharmacology, University of Wisconsin-Madison, 1300 University Avenue, Madison, WI 53706, USA.

Molecular Cell
|April 1, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Nuclear Export Signal of IκBα Drives RelB Oscillations in the Noncanonical NF-κB Pathway.

Genes to cells : devoted to molecular & cellular mechanisms·2026
Same author

Editorial Expression of Concern: YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity.

Oncogene·2026
Same author

Cardiomyocyte YAP represses myocardial inflammation and fibrosis and restrains MEF2-regulated gene expression.

American journal of physiology. Heart and circulatory physiology·2025
Same author

NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage.

Science signaling·2025
Same author

Untangling the role of RhoA in the heart: protective effect and mechanism.

Cell death & disease·2024
Same author

Gα12 signaling regulates transcriptional and phenotypic responses that promote glioblastoma tumor invasion.

Scientific reports·2023
Same journal

Thyroid cancer-associated EZH1 Q571R mutation drives chromatin compaction and H3K27me3 invasion into active chromatin.

Molecular cell·2026
Same journal

Genome-wide rotational and translational phasing of nucleosomes with human transcription factors.

Molecular cell·2026
Same journal

Spliceosomal proofreading factors safeguard 3' splice-site fidelity and prevent proteotoxicity and inflammation.

Molecular cell·2026
Same journal

Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP.

Molecular cell·2026
Same journal

A bacterial reverse transcriptase: Protein-templated DNA synthesis fuels antiviral immunity.

Molecular cell·2026
Same journal

Tweezing apart ribosome heterogeneity.

Molecular cell·2026
See all related articles

Anticancer drugs reprogram RelA, a protein usually promoting cell survival, to instead trigger cell death. This unexpected role involves RelA actively suppressing survival genes, leading to apoptosis.

Area of Science:

  • Molecular biology
  • Cellular signaling
  • Cancer research

Background:

  • RelA (also known as NF-κB p65) is a transcription factor primarily recognized for activating genes that promote cell survival and inhibit apoptosis.
  • The established role of RelA in prosurvival pathways is critical in various cellular contexts, including cancer development and progression.

Purpose of the Study:

  • To investigate the role of RelA in response to anticancer drug treatment.
  • To determine if RelA's function can be altered from prosurvival to pro-apoptotic under specific conditions.

Main Methods:

  • Analysis of gene transcription patterns in cancer cells treated with anticancer drugs.
  • Assessment of RelA binding to target gene promoters.
  • Evaluation of apoptosis induction and survival gene expression levels.

Related Experiment Videos

Main Results:

  • Anticancer drugs induce a functional switch in RelA.
  • RelA actively represses the transcription of key survival genes.
  • This repression by RelA promotes drug-induced apoptosis.

Conclusions:

  • RelA can act as a repressor of survival genes, promoting apoptosis in the presence of anticancer drugs.
  • This finding reveals a novel mechanism by which cancer therapies induce cell death.
  • Targeting this altered function of RelA could offer new therapeutic strategies.